Synthego is a privately held, genome engineering innovation company headquartered in Redwood, California and was founded in 2012 by Alex Pesch, Michael Dabrowski, Paul Dabrowski. It focuses on providing broader access to CRISPR to accelerate basic scientific discovery, research cures for diseases, and develop novel synthetic biology applications through the company's automated, full stack genome engineering platform.
The company's product portfolio is divided into two areas: engineered cells and CRISPR kits. Under the engineered cells, Synthego offers knockout cell pools, knockout cell clone, and advanced cells with the client's custom edits. Under the CRISPR kits, it offers synthetic sgRNA kits, gene knockout kits, CRISPR screening libraries, advanced RNA, and synthetic cr:tracrRNA kits.
In Jan 2017, Synthego had secured $41 million in funding from investors including, Jennifer A. Doudna, 8VC, and Founders Fund. Recently, in October 2018, it raised another $110 million in Series C funding round. The round was led by Founders Fund, with additional investment from existing investors 8VC and Menlo Ventures. Synthego's total funding is about $160 million.
Timeline
Funding rounds
People
A David Edward Camobell
Private Investor
Andrew Garvin
Investor
Bob Molinari
Advisor
Bobby Moon
Employee
Brandon Whitney
Employee
Brendon Sassmannshaus
Employee
Fabian Gerlinghaus
Employee
Faytan Campbell
Investor
Jacob Creedon
Employee
Jeff Pace
Employee
Joanne C. Lohrasbpour
Employee
John Walker
Employee
Joshua Vasquez
Employee
Jun Axup, PhD
Employee
Kelly Hoppensteadt
Employee
Kent Kemmish
Employee
Kevin Holden
Employee
Lawrence Chou
Employee
Matt Mazurek
Employee
Michael Dabrowski
Founder
Moshen Chan
Investor
Myo Thu
Employee
Omar Kurdi
Employee
Pamela Solon
Employee
Paul Dabrowski
Founder